UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-QSB

[X]

QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

|For the quarterly period ended March 31, 2004
|---------------------------------------------

[ ]

TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT

|For the transition period from | to
|------------------------------ | --

000-31469

(Commission file number)

MEDICALINTERNATIONALTECHNOLOGY,INC.

(Exact name of small business issuer as specified in its charter)

|Colorado                         
|---------------------------------
|                                 
|(State or other jurisdiction     
|of incorporation or organization)

|84-1509950         
|-------------------
|                   
|(IRS Employer      
|Identification No.)

2281 Guenette Ville Saint-Laurent

Montreal, Quebec, Canada HR4 2E9

(Address of principal executive offices)

(514) 339-9355

(Issuer's telephone number)

(Former name, former address and former fiscal year, if changed since last report)

[X]

Check whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90 days.

The number of shares outstanding of each of the issuer's classes of common equity as of March 31, 2004 - 25,170,400 shares of common stock

Transitional Small Business Disclosure Format (check one): Yes [ ] No [X]

---

Medical International Technology, Inc.

Quarterly Financial Report

Index

|           |                                                             | Page   | 
|---------- | ----------------------------------------------------------- | ------ | 
|           |                                                             | Number | 
|           |                                                             |        | 
|           |                                                             |        | 
|PART I.    | FINANCIAL INFORMATION                                       |        | 
|           |                                                             |        | 
|Item 1.    | Consolidated Financial Statements                           |        | 
|           |                                                             |        | 
|           | Consolidated Balance Sheet, March 31, 2004 (Unaudited)      | 4      | 
|           |                                                             |        | 
|           | Consolidated Statements of Operations,                      |        | 
|           | three-months ended March 31, 2004 and 2003 (Unaudited),     |        | 
|           | six-months ended March 31, 2004 and 2003 (Unaudited)        | 5      | 
|           |                                                             |        | 
|           | Consolidated Statements of Cash Flows,                      |        | 
|           | six-months ended March 31, 2004 and 2003 (Unaudited)        | 6      | 
|           |                                                             |        | 
|           | Notes to Unaudited Consolidated Financial Statements        | 7      | 
|           |                                                             |        | 
|Item 2.    | Management's Discussion and Analysis of Financial Condition |        | 
|           | and Plan of Operations                                      | 10     | 
|           |                                                             |        | 
|Item 3.    | Controls and Procedures                                     | 11     | 
|           |                                                             |        | 
|Part II.   | OTHER INFORMATION                                           |        | 
|           |                                                             |        | 
|Item 1.    | Legal Proceedings                                           | 12     | 
|           |                                                             |        | 
|Item 2.    | Defaults Upon Senior Securities                             | 12     | 
|           |                                                             |        | 
|Item 3.    | Submission of Matters to a Vote of Security Holders         | 12     | 
|           |                                                             |        | 
|Item 4.    | Other Information                                           | 12     | 
|           |                                                             |        | 
|Item 5.    | Exhibits and Reports on Form 8-K                            | 12     | 
|           |                                                             |        | 
|SIGNATURES | 12                                                          |       

---

PART I. FINANCIAL INFORMATION

ITEM 1. Consolidated Financial Statements

Consolidated Balance Sheet March 31, 2004 (Unaudited)

and

Consolidated Statements of Operations for the 3-month period ended March 31, 2004 and 2003 (Unaudited)

and

for the 6 month period ended March 31, 2004 and 2003 (Unaudited)

and

Consolidated Statements of Cash Flows for the 6-month period ended March 31, 2004 and 2003 (Unaudited)

and

Notes to Unaudited Consolidated Financial Statements

---

Medical International Technology, Inc.  	Quarterly Financial Report

|Consolidated Balance Sheet                                      |      |                |             | 
|--------------------------------------------------------------- | ---- | -------------- | ----------- | 
|                                                                |      |                |             | 
|                                                                |      | March 31, 2004 |            
|                                                                |      |                |            
|                                                                |      | (Unaudited)    |            
|Assets                                                          |      |                |            
|Current Assets                                                  |      |                |            
|Cash and cash equivalents                                       |      | $              | 25,357      | 
|Inventories                                                     |      |                | 69,852      | 
|Receivable from related parties                                 |      |                | 69,912      | 
|Research tax credit receivable                                  |      |                | 111,210     | 
|                                                                |      |                |             | 
|Total Current Assets                                            |      |                | 276,331     | 
|                                                                |      |                |             | 
|                                                                |      |                |             | 
|Property and Equipment                                          |      |                |             | 
|Tooling and machinery                                           |      |                | 210,768     | 
|Furniture and office equipment                                  |      |                | 61,328      | 
|Leasehold improvements                                          |      |                | 22,893      | 
|                                                                |      |                |             | 
|                                                                |      |                | 294,989     | 
|Less accumulated depreciation                                   |      |                | (102,450)   | 
|                                                                |      |                |             | 
|                                                                |      |                | 192,539     | 
|                                                                |      |                |             | 
|Other Assets                                                    |      |                |             | 
|Intangible assets subject to amortization                       |      |                |             | 
|Patents (net accumulated amortization of $                      | 509) |                | 4,955       | 
|                                                                |      |                |             | 
|Total Assets                                                    |      | $              | 473,825     | 
|                                                                |      |                |             | 
|                                                                |      |                |             | 
|Liabilities and Stockholders' (Deficit)                         |      |                |             | 
|Current Liabilities                                             |      |                |             | 
|Unearned income                                                 |      | $              | 55,555      | 
|Accounts payable                                                |      |                | 125,367     | 
|Accounts payable - related parties                              |      |                | 15,000      | 
|Accrued expenses                                                |      |                | 5,107       | 
|Loans payable - related parties                                 |      |                | 380,175     | 
|Loans payable                                                   |      |                | 273,803     | 
|Current portion of long-term debt                               |      |                | 20,880      | 
|                                                                |      |                |             | 
|Total Current Liabilities                                       |      |                | 875,887     | 
|                                                                |      |                |             | 
|Long-Term Debt                                                  |      |                | 17,625      | 
|                                                                |      |                |             | 
|Total Liabilities                                               |      |                | 893,512     | 
|                                                                |      |                |             | 
|Redeemable Class E Stock                                        |      |                | -           | 
|Stockholders' (Deficit)                                         |      |                |             | 
|Preferred stock, $.0001 par value; 3,000,000 shares authorized; |      |                |            
|none issued and outstanding as of December 31, 2003             |      | -              |            
|Common stock, $.0001 par value; 30,000,000 shares authorized;   |      |                |            
|issued and outstanding 25,170,400 shares as of March 31, 2004   |      | 2,517          |            
|Additional paid-in capital                                      |      |                | 2,950,870   | 
|Retained (deficit)                                              |      |                | (3,365,078) | 
|Other comprehensive loss                                        |      |                | (7,996)     | 
|                                                                |      |                |             | 
|Total Stockholders' (Deficit)                                   |      |                | (419,687)   | 
|                                                                |      |                |             | 
|                                                                |      |                |             | 
|Total Liabilities and Stockholders' (Deficit)                   | $    | 473,825        |            
|                                                                |      |                |            

The accompanying notes are an integral part of these consolidated financial statements

4

---

Medical International Technology, Inc.  	Quarterly Financial Report

|Consolidated Statements of Operations         |                            |             |           |                          |             |          |           |            |             |   |            |             |        |   |           |          |   |        | 
|--------------------------------------------- | -------------------------- | ----------- | --------- | ------------------------ | ----------- | -------- | --------- | ---------- | ----------- | - | ---------- | ----------- | ------ | - | --------- | -------- | - | ------ | 
|                                              |                            |             |           |                          |             |          |           |            |             |   |            |             |        |   |           |          |   |        | 
|                                              |                            |             |           |                          |             |          |           |            |             |   |            |             |        |   |           |          |   |        | 
|                                              | For the Three-Months Ended |             |           | For the Six-Months Ended |            
|                                              |                            | March 31,   |           |                          |             | March 31 |           |           
|                                              |                            | 2004        |           |                          | 2003        |          |           | 2004       |             |   | 2003       |            
|                                              |                            |             |           |                          |             |          |           |            |             |   |            |            
|                                              |                            | (Unaudited) |           |                          | (Unaudited) |          |           |            | (Unaudited) |   |            | (Unaudited) |       
|                                              |                            |             |           |                          |             |          |           |            |             |   |            |             |        |   |           |          |   |        | 
|Sales                                         | $                          |             | 49,467    |                          | $           |          | 59,218    |            | $           |   | 93,360     |             | $      |   | 185,682   |         
|Cost of sales                                 |                            |             | (24,220)  |                          |             |          | (30,338)  |            |             |   | (41,502)   |             |        |   | (93,135)  |         
|                                              |                            |             |           |                          |             |          |           |            |             |   |            |             |        |   |           |         
|Gross profit                                  |                            |             | 25,247    |                          |             |          | 28,880    |            |             |   | 51,858     |             |        |   | 92,547    |         
|                                              |                            |             |           |                          |             |          |           |            |             |   |            |             |        |   |           |          |   |        | 
|Research and development costs                |                            |             | (34,970)  |                          |             |          |           | -          |             |   |            | (60,321)    |        |   |           |          | - |       
|Selling, general, and administrative expenses |                            |             | (45,777)  |                          |             |          | (260,013) |            |             |   | (79,762)   |             |        |   | (304,766) |         
|                                              |                            |             |           |                          |             |          |           |            |             |   |            |             |        |   |           |         
|                                              |                            |             |           |                          |             |          |           |            |             |   |            |             |        |   |           |          |   |        | 
|Net loss before consulting fees               |                            |             | (55,500)  |                          |             |          | (231,133) |            |             |   | (88,225)   |             |        |   | (212,219) |         
|                                              |                            |             |           |                          |             |          |           |            |             |   |            |             |        |   |           |          |   |        | 
|Consulting fees, non-cash                     |                            |             | (38,726)  |                          |             |          |           | -          |             |   |            | (881,536)   |        |   |           | (99,175) |  
|                                              |                            |             |           |                          |             |          |           |            |             |   |            |             |        |   |           |          |  
|                                              |                            |             |           |                          |             |          |           |            |             |   |            |             |        |   |           |          |   |        | 
|Net loss from operations                      |                            |             | (94,226)  |                          |             |          | (231,133) |            |             |   | (969,761)  |             |        |   | (311,394) |         
|                                              |                            |             |           |                          |             |          |           |            |             |   |            |             |        |   |           |          |   |        | 
|Other Income (Expense)                        |                            |             |           |                          |             |          |           |            |             |   |            |             |        |   |           |          |   |        | 
|Interest income                               |                            |             | 8         |                          |             |          |           | -          |             |   |            |             | 8      |   |           |          |   | 517    | 
|Interest expense                              |                            |             | (10,568)  |                          |             |          | (9,522)   |            |             |   | (18,642)   |             |        |   | (18,518)  |         
|                                              |                            |             |           |                          |             |          |           |            |             |   |            |             |        |   |           |         
|                                              |                            |             |           |                          |             |          |           |            |             |   |            |             |        |   |           |          |   |        | 
|Net loss                                      |                            | $           | (104,786) |                          |             | $        | (240,655) |            |             | $ | (988,395)  |             |        | $ | (329,395) |         
|                                              |                            |             |           |                          |             |          |           |            |             |   |            |             |        |   |           |         
|                                              |                            |             |           |                          |             |          |           |            |             |   |            |             |        |   |           |          |   |        | 
|                                              |                            |             |           |                          |             |          |           |            |             |   |            |             |        |   |           |          |   |        | 
|Basic loss per share                          |                            | $           | *         |                          |             |          | $         | (0.01)     |             |   |            | $           | (0.04) |   |           |          | $ | (0.02) | 
|                                              |                            |             |           |                          |             |          |           |            |             |   |            |             |        |   |           |          |   |        | 
|                                              |                            |             |           |                          |             |          |           |            |             |   |            |             |        |   |           |          |   |        | 
|Basic weighted average shares outstanding     |                            | 24,678,114  |           |                          | 18,407,022  |          |           | 24,678,114 |             |   | 18,313,284 |            
|                                              |                            |             |           |                          |             |          |           |            |             |   |            |            
|                                              |                            |             |           |                          |             |          |           |            |             |   |            |             |        |   |           |          |   |        | 
|                                              |                            |             |           |                          |             |          |           |            |             |   |            |             |        |   |           |          |   |        | 
|                                              |                            |             |           |                          |             |          |           |            |             |   |            |             |        |   |           |          |   |        | 
|                                              |                            |             |           |                          |             |          |           |            |             |   |            |             |        |   |           |          |   |        | 
|* Less than $(0.01) loss per share            |                            |             |           |                          |             |          |           |            |             |   |            |             |        |   |           |          |   |        | 

The accompanying notes are an integral part of these consolidated financial statements

5

---

Medical International Technology, Inc.  	Quarterly Financial Report

|Consolidated Statements of Cash Flows                        |                          |           |                |   |           | 
|------------------------------------------------------------ | ------------------------ | --------- | -------------- | - | --------- | 
|                                                             |                          |           |                |   |           | 
|                                                             |                          |           |                |   |           | 
|                                                             | For the Six-Months Ended |          
|                                                             | March 31, 2004           |           | March 31, 2003 |  
|                                                             |                          |           |                |  
|                                                             | (Unaudited)              |           | (Unaudited)    |  
|Cash Flows from Operating Activities                         |                          |           |                |  
|Net loss                                                     | $                        | (988,395) |                | $ | (329,395) | 
|Adjustments to reconcile net loss to net cash                |                          |           |                |   |           | 
|used in operating activities:                                |                          |           |                |   |           | 
|Depreciation expense                                         |                          | 22,960    |                |   | 19,314    | 
|Amortization expense                                         |                          | 124       |                |   | 218       | 
|Common stock issued for consulting and legal services        |                          | 881,536   |                |   | 99,175    | 
|Accrued interest expense on indebtedness                     |                          | 5,107     |                |   | 10,078    | 
|(Increase) Decrease in Assets                                |                          |           |                |   |           | 
|Decrease in accounts receivable                              |                          | 29,622    |                |   | 834       | 
|Decrease in receivable from taxing authorities               |                          | 48,312    |                |   | 131,834   | 
|(Increase) in inventories                                    |                          | (27,526)  |                |   | (115,995) | 
|(Increase) in prepaid expenses                               |                          | -         |                |   | (3,552)   | 
|Increase (Decrease) in Liabilities                           |                          |           |                |   |           | 
|(Decrease) increase in unearned income                       |                          | (2,198)   |                |   | 42,099    | 
|Increase (decrease) in accounts payable and accrued expenses |                          | 22,494    |                |   | 110,161   | 
|                                                             |                          |           |                |   |           | 
|                                                             |                          |           |                |   |           | 
|Net Cash Used in Operating Activities                        |                          | (7,964)   |                |   | (35,229)  | 
|                                                             |                          |           |                |   |           | 
|                                                             |                          |           |                |   |           | 
|Cash Flows from Investing Activities                         |                          |           |                |   |           | 
|Equipment acquisition                                        |                          | (3,610)   |                |   | (1,852)   | 
|                                                             |                          |           |                |   |           | 
|                                                             |                          |           |                |   |           | 
|Net cash Used in Investing Activities                        |                          | (3,610)   |                |   | (1,852)   | 
|                                                             |                          |           |                |   |           | 
|                                                             |                          |           |                |   |           | 
|Cash Flows from Financing Activities                         |                          |           |                |   |           | 
|Advances from loans                                          |                          | 37,372    |                |   | -         | 
|Advances from related parties                                |                          | 16,699    |                |   | 301,979   | 
|Advances and repayments to related parties                   |                          | (7,707)   |                |   | (217,939) | 
|Principal reduction on small business loan                   |                          | (8,536)   |                |   | (6,811)   | 
|                                                             |                          |           |                |   |           | 
|                                                             |                          |           |                |   |           | 
|Net Cash Provided by Financing Activities                    |                          | 37,828    |                |   | 77,229    | 
|                                                             |                          |           |                |   |           | 
|                                                             |                          |           |                |   |           | 
|Effect of exchange rates on cash                             |                          | (13,096)  |                |   | 4,664     | 
|                                                             |                          |           |                |   |           | 
|                                                             |                          |           |                |   |           | 
|Net Increase in Cash and Cash Equivalents                    |                          | 13,158    |                |   | 44,812    | 
|Beginning Balance - Cash and Cash Equivalents                |                          | 12,199    |                |   | 41,104    | 
|                                                             |                          |           |                |   |           | 
|Ending Balance - Cash and Cash Equivalents                   | $                        | 25,357    |                | $ | 85,916    | 
|                                                             |                          |           |                |   |           | 
|                                                             |                          |           |                |   |           | 
|Supplemental Information:                                    |                          |           |                |   |           | 
|Cash Paid For:                                               |                          |           |                |   |           | 
|Interest Expenses                                            | $                        | 9,343     |                | $ | 8,440     | 
|                                                             |                          |           |                |   |           | 
|Income Taxes                                                 | $                        | -         |                | $ | -         | 
|                                                             |                          |           |                |   |           | 

The accompanying notes are an integral part of these consolidated financial statements

6

---

Medical International Technology, Inc.  	Quarterly Financial Report

Notes to Unaudited Consolidated Financial Statements

Note 1  Basis of Presentation

Interim Financial Statements

The accompanying unaudited consolidated financial statements are presented in accordance with the requirements for Form 10-QSB and Article 10 of Regulation S-X and Regulation S-B. Accordingly, they do not include all the
disclosures normally required by generally accepted accounting principles. Reference should be made to the Medical International Technology, Inc. (the "Company") Form 10-KSB for the year ended September 30, 2003, for additional disclosures including
a summary of the Company's accounting policies, which have not significantly changed.

Note 2  Summary of Significant Accounting Policies

Principles of consolidation

The accompanying consolidated financial statements include the accounts and transactions of Medical International Technology, Inc. and its wholly owned subsidiary, Medical International Technologies (MIT Canada) Inc.
Intercompany transactions and balances have been eliminated in consolidation.

Foreign Currency Translations

The Company operates out of its offices in Montreal, Canada and maintains its books and records in Canadian Dollars. The consolidated financial statements herein have been converted into U.S. Dollars. Balance sheet accounts
are translated at exchange rates in effect at the end of the period and income statement accounts have been translated at average exchange rates for the period.Translation
gains and losses are included as a separate component of stockholders equity.

Allowance for Doubtful Accounts

The allowance for doubtful accounts on accounts receivable is charged to income in amounts sufficient to maintain the allowance for uncollectible accounts at a level management believes is adequate to cover any probable
losses. Management determines the adequacy of the allowance based on historical write-off percentages and the current status of accounts receivable. Accounts receivable are charged off against the allowance when collectibility is determined to be
permanently impaired. As of March 31, 2004, the Company did not establish any reserve for doubtful accounts.

Inventories

Inventories are stated at the lower of cost determined by the FIFO method or market.

Property and Equipment

The cost of property and equipment is depreciated over the estimated useful lives of the related assets, which range from 5 to 7 years. Depreciation is computed on the straight-line method for financial reporting purposes
and on the declining balance method for income tax reporting purposes. Depreciation expense for the three-months ended March 31, 2004 and 2003were $11,480, and $10,230,
respectively. Depreciation expense for the six-months ended March 31, 2004 and 2003were $22,960, and $19,314, respectively.

Intangible assets

Patents are being amortized over their respective remaining lives ranging from 9.5 years through 17 years.

Net Loss Per Share

The Company adopted the provisions of Statement of Financial Accounting Standards (SFAS) No. 128, Earnings Per Share (EPS) that established standards for the computation, presentation and
disclosure of earnings per share, replacing the presentation of Primary EPS with a presentation of Basic EPS.

7

---

Medical International Technology, Inc.  	Quarterly Financial Report

Notes to Unaudited Consolidated Financial Statements

Issuances Involving Non-cash Consideration

All issuances of the Companys stock for non-cash consideration have been assigned a dollar amount equaling either the market value of the shares issued or the value of consideration received whichever is more readily
determinable.

Cash and Cash Equivalents

For purpose of the statements of cash flows, the Company considers cash and cash equivalents to include all stable, highly liquid investments with maturities of three months or less.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and
liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Long-Lived Assets

In August 2001, SFAS No. 144, "Accounting for the Impairment or Disposal of Long-Lived Assets," was issued establishing new rules and clarifyingimplementation
issues with SFAS No. 121, "Accounting for the Impairment of Long-Lived Assets and for Long-Lived Assets to be Disposed of, "by allowing a probability-weighted cash flow estimation approach to measure the impairment loss of a long-lived asset. The
statement also established new standards for accounting for discontinued operations. Transactions that qualify for reporting in discontinued operations include the disposal of a component of an entity's operations that comprises operations and cash
flow that can be clearly distinguished, operationally and for financial reporting purposes, from the rest of the entity. The Company has adopted this standard and its adoption had no significant effect on the Company's financial
statementsReclassification

Certain amounts in March 31, 2003have been reclassified to conform to the March 31, 2004spresentation. Such reclassification had no effect on net income as previously reported.

Income Taxes

The Company accounts for its income taxes under the provisions of Statement of Financial Accounting Standards 109 ("SFAS 109").  The method of accounting for income taxes under SFAS 109 is an asset and liability method. The
asset and liability method requires the recognition of deferred tax liabilities and assets for the expected future tax consequences of temporary differences between tax bases and financial reporting bases of other assets and liabilities.

Fair Value of Financial Instruments

Pursuant to SFAS No. 107, Disclosures About Fair Value of Financial Instruments, the Company is required to estimate the fair value of all financial instruments included on its balance sheet as of March 31,
2004. The Company considers the carrying value of such amounts in the financial statements to approximate their face value.

Revenue Recognition

The Company recognizes revenue when the related product is shipped to the respective customer.

8

---

Medical International Technology, Inc.  	Quarterly Financial Report

Notes to Unaudited Consolidated Financial Statements

Note 3 - Intangible Assets

Amortization expense for the Six-months ended March 31, 2004and 2003 were $125, and $218, respectively.

Intangible assets consist of the following:

|        |   |            | March 31, 2004 |              |               
|------- | - | ---------- | -------------- | ------------ | --------------
|        |   |            |                |              |               
|        |   | Gross      |                |              |               
|        |   | Intangible |                | Accumulated  |               
|        |   | Assets     |                | Amortization |               
|        |   |            |                |              |               
|Patents | $ | 5,464      |                | $            | 509           
|        |   |            |                |              |               
|        |   |            |                |              | March 31, 2003
|        |   |            |                |              |               
|        |   | Gross      |                |              |               
|        |   | Intangible |                | Accumulated  |               
|        |   | Assets     |                | Amortization |               
|        |   |            |                |              |               
|Patents | $ | 2,419      |                | $            | 406           

Estimated amortization expense for each of the next five years ended December 31, is as follows:

|2004  |  | $ | 226   | 
|----- |  | - | ----- | 
|2005  |  |   | 226   | 
|2006  |  |   | 226   | 
|2007  |  |   | 226   | 
|2008  |  |   | 226   | 
|      |  |   |       | 
|Total |  | $ | 1,130 | 
|      |  |   |       | 

Note 4 - Stock Activity

For the six-months ended March 31, 2004, the Company issued 3,454,800 shares of its common stock for consulting services. The value assigned to these shares totaled $881,536 based upon the market value of the shares on the
date of issuance. Of the 3,454,800, 3,050,000 were issued to the Companys officers, directors and other related parties.

Note 5 - Related Party Transactions

For the six-months ended March 31, 2004, the Company paid consulting services to both of its officers, directors and other related parties through the issuance of 3,050,000 shares valued at $788,000 based upon the market
value of the shares on the date of issuance.

Note 6  Commitment and Contingency

On May 14, 2003 the Company issued 100,000 common shares for services rendered. Due to the lack of value of the shares issued, the creditor has requested additional shares to be issued to make up for the shortfall. The
total amount in dispute is $46,537. The Company is currently negotiating the number of additional shares to issue to resolve the dispute. The ultimate resolution of this action is not expected to have a material adverse effect on the Companys
financial position.

9

---

Medical International Technology, Inc.

Quarterly Financial Report

Item 2. Management's Discussion and Analysis of Financial Condition and Plan of Operations

Forward-Looking Statements

Certain statements concerning the Company's plans and intentions included herein may constitute forward-looking statements for purposes of the Securities Litigation Reform Act of 1995 for which the Company claims a safe
harbor under that Act. There are a number of factors that may affect the future results of the Company, including, but not limited to, (a) the ability of the company to obtain additional funding for operations, (b) the continued availability of
management to develop the business plan and (c) successful development and market acceptance of the companys products.

This periodic report may contain both historical facts and forward-looking statements.  Any forward-looking statements involve risks and uncertainties, including, but not limited to, those mentioned above. Moreover, future
revenue and margin trends cannot be reliably predicted.

All statements that are included in this Quarterly Report, other than statements of historical fact, are forward looking statements. Although management believes that the expectations reflected in these forward looking
statements are reasonable, it can give no assurance that such expectations will prove to have been correct.

Results of Operations for the Three-Months ended March 31, 2004and 2003

For the three-months ended March 31, 2004, the Company experienced a net loss from operations of $104,786, which primarily comprised of research and development expenses of $34,970, selling, general and administrative
expenses of $45,777 and consulting fees of $38,726. The Company experienced a reduction in sales of $9,751 compared to sales for the same period last year. Gross profit for the three-months ended March 31, 2004 was $25,247 or 51% of sales as
compared to 49% for the same period last year.

For the three-months ended March 31, 2003, the Companys net loss from operations was $240,655, which primarily comprised of selling, general and administrative expenses of $260,013. The Company experienced an increase
in sales of $47,909 as compared to the same period last year. Sales for the three-months ended March 31, 2003 were $59,218. Gross profit for same period was $28,880 or 49% of sales.

Results of Operations for the Six-Months ended March 31, 2004and 2003

For the six-months ended March 31, 2004, the Company experienced a net loss from operations of $988,395, which primarily comprised of research and development expenses of $60,321, selling, general and administrative
expenses of $79,762 and consulting fees of $881,536. The Company experienced a reduction in sales of $92,322 compared to sales for the same period last year. As of March 31, 2004, the Company had received $55,555 as advances towards future sales
pertaining to its distribution agreement with WLT Distributors Inc. Gross profit for the six-months ended March 31, 2004 was $51,858 or 56% of sales as compared to 50% for the same period last year.

For the six-months ended March 31, 2003, the Companys net loss from operations was $329,395, which primarily comprised of selling, general and administrative expenses of $304,766 and consulting fees of $99,175. The
Company experienced an increase in sales of $166,478 as compared to the same period last year. The increase is due to the products sold under the various distribution agreements that the Company has with WLT Distributors Inc.

Liquidity and Capital Resources

Cash and cash equivalents increased by $13,158. The Company used $7,964 from its operations and received $37,828 from financing activities. Financing activities included the receipt of a total of $54,071 from related
parties, repayments to related parties of $7,707 and principal reduction in its business loan of $8,536

Cash and cash equivalents as of March 31, 2003 increased by $44,812. The Company used $35,229 from its operations and received $77,229 from financing activities. Financing activities included the receipt of $301,979 from
related parties, repayments to related parties of $217,939 and principal reduction in its business loan of $6,811.

10

---

Medical International Technology, Inc.

Quarterly Financial Report

Management Plan of Operations

Medical International Technology, Inc., is receiving revenues from sales. The company has maintained operations from these revenues and through equity and debt financing. Products are currently developed, assembled and
shipped from our facility. Component manufacturing is subcontracted to various suppliers and machine shops. Within the last Quarter MIT has continued to promote its injectors in many countries including the United States of America, MIT has signed
four Letters of Intent with Distributors in Taiwan, Thailand and the Philippines. These letters of intent represent a commitment to negotiate distribution agreements in good faith and provide no commitment to purchase product at this time.

MIT is exerting every effort and using its resources to promote its products and to open markets for its technology. As we continue to market our products, we hope to gain broader acceptance of the needle-free injection
technology. MIT is continually researching and developing its products to respond to the market needs.

MIT has recently obtained the official certificate of registration from the United States Patent and Trademark office for Trademarks on the use of AGRO-JET (Reg. No. 2,712,089) and MED-JET (Reg. No. 2,798,613).

Medical International Technology, Inc. expects that revenues from existing and developing sales may not meet its liquidity requirements for the next 12 month period at its current level of operations. The company continues
to rely on management to develop the business and work to develop sales. Management has and may continue to supplement cash flows from sales with additional equity and debt financing. Substantially, expanded operations are expected to require
additional capital, either from a future offering of equity or the company pursuing other methods of financing, as appropriate.

Item 3. Controls and Procedures

Medical International Technology, Inc. management, including the Principal Executive Officer and Principal Financial Officer, have conducted an evaluation of the effectiveness of disclosure controls and procedures pursuant
to Exchange Act Rule 13a-14(c) and 15d-14(c). This evaluation was conducted within 90 days prior to the filing of this report. Based on that evaluation, the Principal Executive Officer and Principal Financial Officer concluded that the disclosure
controls and procedures are effective in ensuring that all material information required to be filed in this quarterly report has been made known to them in a timely fashion. There have been no significant changes in internal controls or in other
factors that could significantly affect internal controls subsequent to the date the Principal Executive Officer and Principal Financial Officer completed their evaluation.

11

---

Medical International Technology, Inc.  	Quarterly Financial Report

Part II. OTHER INFORMATION

|Item 1. Legal Proceedings                                  
|-----------------------------------------------------------
|None                                                       
|                                                           
|Item 2. Defaults Upon Senior Securities                    
|None                                                       
|                                                           
|Item 3. Submission of Matters to a Vote of Security Holders
|Not applicable                                             
|                                                           
|Item 4. Other Information                                  
|None                                                       

Item 5. Exhibits and Reports on Form 8-K

Exhibits

Medical International Technology includes herewith the following exhibits.

|31.1 | Certification of Principal Executive Officer pursuant to Section 302  
|---- | ----------------------------------------------------------------------
|31.2 | Certification of Principal Accounting Officer pursuant to Section 302 
|32.1 | Certification of Principal Executive Officer pursuant to Section 1350 
|32.2 | Certification of Principal Accounting Officer pursuant to Section 1350

Reports on Form 8-K

None, during the period ending March 31, 2004.

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

|Medical International Technology, Inc.
|--------------------------------------
|                                      
|Registrant                            

|By: \s\                                                  | Karim Menassa, President
|-------------------------------------------------------- | ------------------------
|                                                        
|Karim Menassa, President and Principal Executive Officer

Date: June 10, 2004

|By: \s\                                                   | Michel Bayouk, Secretary
|--------------------------------------------------------- | ------------------------
|                                                         
|Michel Bayouk, Secretary and Principal Accounting Officer

Date: June 10, 2004

12

---